These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 17166187)

  • 1. Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization.
    van Luijn JC; Gribnau FW; Leufkens HG
    Br J Clin Pharmacol; 2007 Feb; 63(2):159-62. PubMed ID: 17166187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Choice of comparator in active control trials of new drugs.
    van Luijn JC; van Loenen AC; Gribnau FW; Leufkens HG
    Ann Pharmacother; 2008 Nov; 42(11):1605-12. PubMed ID: 18957629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gap in publication of comparative information on new medicines.
    van Luijn JC; Stolk P; Gribnau FW; Leufkens HG
    Br J Clin Pharmacol; 2008 May; 65(5):716-22. PubMed ID: 18294324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The European Regulation on medicines for paediatric use.
    Dunne J
    Paediatr Respir Rev; 2007 Jun; 8(2):177-83. PubMed ID: 17574163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical evaluation of efficacy and adverse effects in the (European) registration of drugs: what does it mean for the doctor and patient?].
    Koopmans PP; de Graeff PA; van Zwieten-Boot BJ; Lekkerkerker JF; Broekmans AW
    Ned Tijdschr Geneeskd; 2000 Apr; 144(16):756-61. PubMed ID: 10812445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparators (medicinal and non medicinal) for marketing authorization, for public health, for payers and at the European level.
    Berdaï D; Hotton JM; Lechat P;
    Therapie; 2010; 65(4):329-34. PubMed ID: 20854755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New preparations comprising recombinant human growth hormone: deliberations on the issue of biosimilars.
    Ranke MB
    Horm Res; 2008; 69(1):22-8. PubMed ID: 18057913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biosimilars: regulatory status for approval].
    Herrero Ambrosio A
    Farm Hosp; 2010 Mar; 34 Suppl 1():16-8. PubMed ID: 20920853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EMEA tackles "generic" biologic drug issues.
    Rice M
    J Natl Cancer Inst; 2006 Apr; 98(7):435-6. PubMed ID: 16595776
    [No Abstract]   [Full Text] [Related]  

  • 13. Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European union.
    Vlietinck A; Pieters L; Apers S
    Planta Med; 2009 Jun; 75(7):683-8. PubMed ID: 19204891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superior efficacy of new medicines?
    van Luijn JC; Gribnau FW; Leufkens HG
    Eur J Clin Pharmacol; 2010 May; 66(5):445-8. PubMed ID: 20224944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role].
    Ainsworth MA
    Ugeskr Laeger; 2003 Apr; 165(16):1648-9. PubMed ID: 12756819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European regulatory guidelines for biosimilars.
    Wiecek A; Mikhail A
    Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v17-20. PubMed ID: 16959790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similar biological medicinal products containing recombinant human growth hormone: European regulation.
    Pavlovic M; Girardin E; Kapetanovic L; Ho K; Trouvin JH
    Horm Res; 2008; 69(1):14-21. PubMed ID: 18059081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. European Union centralised procedure for marketing authorisation of oncology drugs: an in-depth review of its efficiency.
    Netzer T
    Eur J Cancer; 2006 Mar; 42(4):446-55. PubMed ID: 16129598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [European registration of medicines: pros and cons for prescriber and patient].
    Offerhaus L
    Ned Tijdschr Geneeskd; 1997 May; 141(21):1028-33. PubMed ID: 9340558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges in the clinical development requirements for the marketing authorization of new medicines in southeast Asia.
    Kudrin A
    J Clin Pharmacol; 2009 Mar; 49(3):268-80. PubMed ID: 19168433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.